# US 10,945,967 B2 · Formulations of a transdermal patch for pain management

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,967 B2
- Document ID: US10945967B2
- Status: Granted
- Kind: B2
- Application number: 15/732,889
- Filed: 2018-01-16
- Published: 2019-07-18
- Granted: 2021-03-16
- Earliest claimed: 2017-05-30
- Applicants: Jae Wang. Song
- Inventors: Jae Wang. Song
- Web page: https://patentgrep.com/patent/US10945967B2

## CPC

- A61K 9/7038: {Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 31/105: Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185)
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/324: Boswellia, e.g. frankincense
- A61P 29/02: without antiinflammatory effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Various formulations (to be used in the form of a single-segment or multi-segment transdermal patch) of bioactive compounds for pain management are described/disclosed. The multi-segmented transdermal patch can include one or more compatible bioactive compounds in each segment. Furthermore, formulations may include silk fibroin and/or microemulsion/nanoemulsion of bioactive compounds and/or microencapsulation/nanoencapsulation of bioactive compounds.

## Claims

### Claim 1

A transdermal patch for pain management,
comprising:
pharmaceutical formulation of
(a) cannabidiol (CBD) or cannabidiol (CBD) pro-drug;
(b) silk fibroin;
(c) Boswellia serrata extract; and
(d) a bioactive compound astaxanthin.

### Claim 2 (depends on 1)

The transdermal patch according to claim 1, is a single segment transdermal patch.

### Claim 3 (depends on 1)

The transdermal patch according to claim 1, comprises: cannabidiol (CBD) or cannabidiol (CBD) pro-drug in microemulsion.

### Claim 4 (depends on 1)

The transdermal patch according to claim 1, further comprises: a permeation enhancement compound.

### Claim 5

A transdermal patch for pain management,
comprising:
pharmaceutical formulation of
(a) cannabidiol (CBD) or cannabidiol (CBD) pro-drug;
(b) cannabichromene (CBC) or cannabichromene (CBC) pro-drug;
(c) silk fibroin;
(d) Boswellia serrata extract; and
(e) a bioactive compound astaxanthin.

### Claim 6 (depends on 5)

The transdermal patch according to claim 5, is a single segment transdermal patch.

### Claim 7 (depends on 5)

The transdermal patch according to claim 5, comprises: cannabidiol (CBD) or cannabidiol (CBD) pro-drug in microemulsion.

### Claim 8 (depends on 5)

The transdermal patch according to claim 5, further comprises: a permeation enhancement compound.

### Claim 9

A transdermal patch for pain management,
comprising:
pharmaceutical formulation of
(a) cannabidiol or cannabidiol pro-drug;
(b) cannabichromene or cannabichromene pro-drug;
(c) Boswellia serrata extract or capsaicin;
(d) silk fibroin; and
(e) a bioactive compound astaxanthin.

### Claim 10

A transdermal patch for pain management,
comprising:
pharmaceutical formulation of
(a) Boswellia serrata extract;
(b) capsaicin;
(c) silk fibroin, and
(d) a bioactive compound astaxanthin.

### Claim 11 (depends on 10)

The transdermal patch according to claim 10, is a single segment transdermal patch.

### Claim 12 (depends on 10)

The transdermal patch according to claim 10, further comprises: a permeation enhancement compound.